Although our patient cohort contained only two REL patients, which clearly poses limitations on drawing general conclusions, this advocates for further exploring ADGRG1 expression by all subsets of cytotoxic T cells in the peripheral blood as a general and easily accessible biomarker for monitoring and predicting AML remission after alloHSCT. Here, ADGRG1 is linked to acute myeloid leukemia.